The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Size Of The Hepatitis B Virus (HBV) Market Progress Through 2030?
The hepatitis b virus (hbv) market has shown strong expansion over recent years. It is anticipated to grow from $7.31 billion in 2025 to $7.98 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.3%. Historically, this growth can be linked to the significant prevalence of hbv in Asia-Pacific, insufficient awareness about hbv treatment, low vaccination uptake in prior years, a reliance on generic antiviral drugs, and an increasing incidence of chronic liver disease.
The market size for the hepatitis B virus (HBV) is anticipated to undergo swift expansion in the coming years, with projections indicating it will reach $11.77 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.2%. This expected growth during the forecast period is primarily due to increasing research and development activities in HBV therapeutics, the broadening reach of government vaccination programs, the embrace of precision medicine, a surge in healthcare expenditure, and advancements in screening and diagnostic infrastructure. Furthermore, significant trends shaping the forecast period include a greater adoption of antiviral therapies, an escalation in hepatitis B vaccination initiatives, the development of combination therapies, a concentrated effort on managing HBV in both pediatric and geriatric populations, and the extension of screening and diagnostic services.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12867&type=smp
What Influential Factors Are Boosting The Hepatitis B Virus (HBV) Market Demand?
The extensive occurrence of hepatitis B infection is anticipated to propel the expansion of the hepatitis B virus market going forward. Hepatitis B is a liver ailment caused by the hepatitis B virus (HBV), which is preventable through vaccination. Rising hepatitis B infection rates can increase the need for diagnostic tests and treatment options. For instance, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency focusing on the control and prevention of disease, injury, and disability, an estimated 13,300 new hepatitis B infections and 69,800 new hepatitis C infections occurred in 2023. Therefore, the high prevalence of hepatitis B infection will drive the hepatitis B virus market.
How Is The Hepatitis B Virus (HBV) Market Examined Through Segment Analysis?
The hepatitis b virus (hbv) market covered in this report is segmented –
1) By Type: Acute, Chronic
2) By Treatment: Immune Modulator Drugs, Antiviral Drugs, Vaccine, Surgery
3) By Age Group: Pediatrics, Adults, Seniors
4) By End User: Medical Providers, Patients, Healthcare Payers
Subsegments:
1) By Acute HBV: Asymptomatic Acute HBV, Symptomatic Acute HBV, Severe Acute HBV
2) By Chronic HBV: Chronic Hepatitis B (HBeAg Positive), Chronic Hepatitis B (HBeAg Negative), Chronic Hepatitis B With Compensated Liver Disease, Chronic Hepatitis B With Decompensated Liver Disease, Chronic Hepatitis B With Hepatocellular Carcinoma (HCC)
Which Trends Are Contributing To Changes In The Hepatitis B Virus (HBV) Market?
Leading firms within the HBV market are prioritizing the development of novel treatments through clinical studies and expediting regulatory approvals to boost treatment effectiveness and secure a competitive edge. As an illustration, Aligos Therapeutics, a US-based therapeutic firm, initiated patient dosing for its Phase II B-SUPREME trial of ALG-000184, an inaugural oral capsid assembly modulator designed for chronic hepatitis B, in August 2025. This randomized, double-blind investigation plans to recruit approximately 200 adults who have not received prior treatment, comparing ALG-000184 against tenofovir disoproxil fumarate for a duration of 48 weeks. The main objective is to attain HBV DNA levels below detectable thresholds in both HBeAg-positive and HBeAg-negative individuals, alongside secondary assessments of safety, pharmacokinetics, and antigen alterations. Previous Phase I data demonstrated robust antiviral efficacy and favorable tolerability, substantiating the drug’s promise. Preliminary results are projected for 2026, and complete topline findings are foreseen in 2027.
Who Are The Firms Contributing To The Hepatitis B Virus (HBV) Market Ecosystem?
Major companies operating in the hepatitis b virus (hbv) market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sanofi SA, GlaxoSmithKline PLC, Gilead Sciences Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Apotex Corp., Lupin Pharmaceuticals Inc., Cadila Healthcare Ltd., Dynavax Technologies Corporation, Accord Healthcare Inc., Par Pharmaceutical Inc., Arbutus Biopharma Corporation, Antios Therapeutics Inc.
Access The Complete Hepatitis B Virus (HBV) Market Report:
https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report
Which Region Contributes The Most To The Hepatitis B Virus (HBV) Market?
North America was the largest region in the hepatitis B Virus (HBV) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis b virus (hbv) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Hepatitis B Virus (HBV) Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=12867&type=smp
Browse Through More Reports Similar to the Global Hepatitis B Virus (HBV) Market 2026, By The Business Research Company
Hepatitis B Virus Hbv Market Report 2026
https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report
Chronic Hepatitis B Market Report 2026
https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report
Preventive Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model